Figure 7.

NG2 silencing does not impair the tumorigenic potential of cells derived from PDGF-B-induced tumors. (A-B) Immunofluorescence stainings of PDGF-B-induced glioma cultures transduced with miR-NG2 (A) or miRneg (B) and stained with anti-GFP antibody in green, anti-NG2 antibody in red and DAPI (nuclei) in blue. (C-D) Histograms showing the efficiency of miR-NG2 silencing in PDGF-B-induced glioma cultures (C) or in cells extracted from a secondary tumor generated by the intracranial injection of PDGF-B-induced glioma cells previously transduced with miR-NG2 (miR-NG2 secondary tumor; D). GFP positive cells represent glioma cells which were actually transduced with miR-NG2, while GFP-negative cells were not transduced. (E) Fluorescence image of a miR-NG2 secondary tumor. (F) Immunofluorescence staining of miR-NG2 secondary tumor cells with anti-GFP antibody in green, anti-NG2 antibody in red and DAPI (nuclei) in blue. Scale bars: 50 μm (A-B, F); 0.5 mm (E).

Terrile et al. BMC Cancer 2010 10:550   doi:10.1186/1471-2407-10-550
Download authors' original image